Clinical Trial Update: P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 study of brodalumab in moderate to severe plaque psoriasis has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• To Severe Plaque Psoriasis

Drugs mentioned

• brodalumab (brodalumab)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Moderate to Severe Plaque Psoriasis | Phase 3 | Status: TERMINATED | Results posted: 2020-01-06